tbuckley/cabot-search huggingface dataset:
Antiemesis
Authors: _ _
Journal: Journal of the National Comprehensive Cancer Network (2007)

Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. For the most recent version of the guidelines, please visit NCCN.org
Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.
Authors: Aditya Bardia, Dejan Juric, Steven J. Isakoff, Darrell R. Borger, Dora Dias-Santagata, Michaela Jane Higgins, Anthony John Iafrate, Keith Flaherty, Beverly Moy, Leif William Ellisen
Journal: Journal of Clinical Oncology (2013)

145 Background: Major barriers to enrollment in therapeutic clinical trials (&lt;5% in United States) include low response rate in phase I/II trials and low enthusiasm among oncologists. Stratified clinical trial enrollment based on molecular profiling of tumors represents a potential paradigm shift in drug development. Here we assess the clinical utility of tumor genotyping for identification of oncogenic driver mutations and enrollment in therapeutic clinical trials for patients with metastatic breast cancer (MBC). Methods: A robust, high-throughput tumor genotyping assay (Snapshot), was developed at our institution to assess for presence of potentially actionable oncogenic driver mutations (15 genes, 130 mutations) using DNA derived from formalin-fixed, paraffin-embedded (FFPE) tissue. The tumor genotyping assay was ordered by oncologists in clinic for patients with MBC. Relevant clinical information was gathered from chart reviews. Descriptive statistics were used for analysis. Results: From 2009-2012, 347 breast tumors were prospectively genotyped in the study population (median age = 50, range 27-90). The common oncogenic mutations were seen in all breast cancer subtypes. PIK3CA mutation (23.3%) was the most common mutation detected overall, albeit at varying frequency in tumor subtypes: HR+ (29.1%, N= 210), HER-2+ (21.5%, N = 65), TN (8.3%, N = 72). Unanticipated mutations in KRAS, BRAF, IDH, and HER-2 were also discovered. Clinical genotyping helped identify breast origin for carcinomas of unknown primary and revealed changes in mutation profile in metastatic tumors from primary tumors. Enrollment in clinical trials for MBC almost quadrupled from 2005-2008 to 2009-2012, with approximately one-third of patients undergoing tumor genotype testing enrolling in clinical trials, particularly phase-I genotype-directed targeted therapy, such as PI3K inhibitor, Akt inhibitor, and PI3K/MEK inhibitor combination. Conclusions: Routine tumor genotyping can be successfully incorporated into clinical practice to significantly enhance therapeutic clinical trial enrollment and potentially accelerate development of genotype-directed targeted therapies for MBC.
STUDIES IN BASAL METABOLISM
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pathological Contributions to Medical Jurisprudence
Authors: W. B. Mushet
Journal: BMJ (1859)

cover a multitude of sins, and cloke diseases to which it has no resemblance.Let us be careful, whilst we seek to suppress quackery, we do not permit any faslhionable title to be used, on medical autthority at least, which the pretender might turn as a weapon aaainst us, with the rebuke " tu quoque".I would offer these remarks with much diffidence, simply adding, " Si quid novisti rectius istis, Candidus imperti: si non, his utere mecum.
Leukopenia following treatment with thiothixene and haloperidol
Authors: N. R. Cutler
Journal: JAMA (1979)

BLOOD dyscrasias are known to occur in patients treated with phenothiazine-like antipsychotic drugs but are rarely associated with both thiothixene and haloperidol.<sup>1</sup>We report a case of leukopenia that developed in a patient on two separate occasions following treatment with thiothixene and haloperidol, respectively. <h3>Report of a Case</h3> A 27-year-old man was hospitalized after lye ingestion with suicidal intent. Physical examination was remarkable only for severe burns of the pharynx, trachea, and esophagus. His initial hematologic evaluation showed the following values: hemoglobin, 13.3 g/dL; hematocrit, 42.6%; leukocytes, 13,000/cu mm, with 93% polymorphonuclear leukocytes, 6% lymphocytes, and 1% monocytes; and platelets, 235,000/cu mm. The patient had no history of allergies or hematologic problems. Results of both a physical and a laboratory examination, including a complete blood cell count (CBC), four months before admission were normal. His condition had been diagnosed as paranoid schizophrenic for the past four years, and for
Inflammatory left ventricular microaneurysms associated with apparently idiopathic ventricular tachyarrhythmias Cristina Chimenti, Fiorella Calabrese, Gaetano Thiene, Maurizio Pieroni, Attilio Maseri, Andrea Frustaci. Catholic University-Department of Cardiology, Rome, Italy, University of Padua-Department of Pathology, Padua, Italy
Journal: Journal of the American College of Cardiology (2001)
The Croonian Lectures on the Pulse
Authors: W. H. Broadbent
Journal: BMJ (1887)

PusDNr mmD GOrLwmN,-M-y first lectur was ooccpied by oertain general considerations with regard to the puls, after which I began to describe the more important variations in frequency and abnormalities of rhythm.The next to be considered i the infrequent PUI I/reuqMnt Pulse.-It has already been remarked that the effect upon the pulse of nearly all departures from a normal state of halth is to increas its frequency, and the disases are extremely few which reduce the pulse-rate in any marked degree.High tension In the
New treatment regimens help children with malignant lymphoma
Authors: J. F. Henahan
Journal: JAMA (1984)

Improved remission rates and long-term disease-free survival in some children with Hodgkin's disease and non-Hodgkin's lymphoma may now be expected. That is the indication, at least, from reports presented by investigators from several cancer centers at the Second International Conference on Malignant Lymphoma, held in Lugano, Switzerland. <h3>Only Time Will Tell</h3> Although the studies reported at the Lugano conference strongly indicate that extremely high remission rates and apparent long-term survival can be achieved in pediatric patients with lymphomas, using regimens designed to reduce the potential late effects of treatment (leukemia, sterility, and cardiac problems), most participants agree that only time will tell if the new methods really achieve that end. For example, Eli Glatstein, MD, of the National Cancer Institute, Bethesda, Md, said that, in the treatment of pediatric lymphomas, it is still not clear whether the obvious benefits of cure at the present time will be clouded by other
Prostanoids for Chronic Critical Leg Ischemia
Journal: Annals of Internal Medicine (1999)

Background: No effective pharmacologic intervention is available for critical leg ischemia, a severe clinical condition associated with high morbidity and mortality. Objective: To assess the safety and efficacy of prostaglandin E1 in improving the prognosis and quality of life in patients with critical leg ischemia. Design: Multicenter, centrally randomized, controlled, open-label trial. Setting: 56 vascular surgery and angiology departments of the Italian National Health Service. Patients: 1560 patients with chronic critical leg ischemia. Interventions: In addition to routine treatments practiced in each center, patients were randomly assigned to receive either a daily intravenous infusion of 60 µg of prostaglandin E1 in the form of alprostadil-α-cyclodextrine (n = 771) or no prostaglandin E1 (n = 789) during their hospital stay. The treatment period lasted for up to 28 days. Measurements: A combined end point consisting of death and peripheral and cardiocerebrovascular illness (major amputation or persistence of critical leg ischemia, acute myocardial infarction, or stroke) evaluated at hospital discharge and during 6 months of follow-up. Results: The incidence of the combined outcome measure was lower in the alprostadil group than in controls at hospital discharge (493 [63.9%] patients compared with 581 [73.6%] patients; relative risk, 0.87 [95% CI, 0.81 to 0.93]; P < 0.001) but differed only modestly at 6 months (348 of 661 [52.6%] patients compared with 387 of 673 [57.5%] patients; relative risk, 0.92 [CI, 0.83 to 1.01]; P = 0.074). Most of the observed benefit was due to recovery from critical leg ischemia. Conclusions: Short-term treatment with alprostadil-α-cyclodextrine provides patients with critical leg ischemia clinical benefit that is apparent in the short term but decreases over time. *For members of the ICAI (Ischemia Cronica Critica degli Arti Inferiori) Study Group, see the Appendix.
Insulin Administration
Journal: Diabetes Care (1993)

The injection of insulin is essential for management of patients with type 1 diabetes and may be needed by patients with type 2 diabetes for intermittent or continuous glycemic control. The species and dosage of insulin used should be consistent, and the patient's injection technique should be reviewed periodically with the diabetes-care team. The effective use of insulin to obtain the best metabolic control requires an understanding of the duration of action of the various types of insulin and the relationship of blood glucose levels to exercise, food intake, intercurrent illness, certain medications, and stress; SMBG; and learning to adjust insulin dosage to achieve the individualized target goals established between the patient, family, and diabetes-care team.
Interstitial, Not Epithelial.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BLOOD PRESSURE CHANGES DURING ABDOMINAL OPERATIONS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group.
Authors: A Doyle
Journal: BMJ (1991)

OBJECTIVE--To compare the efficacy of angiotensin converting enzyme inhibition with calcium antagonism in diabetic patients with microalbuminuria. DESIGN--Randomised study of diabetic patients with microalbuminuria treated with perindopril or nifedipine for 12 months and monitored for one or three months after stopping treatment depending on whether they were hypertensive or normotensive. Patients were randomised separately according to whether they were hypertensive or normotensive. SETTING--Diabetic clinics in three university teaching hospitals. PATIENTS--50 diabetic patients with persistent microalbuminuria. In all, 43 completed the study: 30 were normotensive and 13 hypertensive; 19 had type I diabetes and 24 had type II diabetes. INTERVENTIONS--For 12 months 20 patients were given perindopril 2-8 mg daily and 23 were given nifedipine 20-80 mg daily. MAIN OUTCOME MEASURES--Albumin excretion rate, blood pressure, and glomerular filtration rate. RESULTS--Both perindopril and nifedipine significantly reduced mean blood pressure. During treatment there was no significant difference between those treated with perindopril and those treated with nifedipine with respect to albuminuria or mean blood pressure. Stopping treatment with both drugs was associated with a sustained increase in albuminuria and mean blood pressure. There was a significant correlation between mean blood pressure and albuminuria and also between the reduction in mean blood pressure and the decrease in albuminuria during treatment with both drugs. In hypertensive patients both drugs caused significant decreases in mean blood pressure and albuminuria. In normotensive patients there was no significant reduction in albuminuria with either regimen. CONCLUSIONS--In diabetic patients with microalbuminuria blood pressure seems to be an important determinant of urinary albumin excretion. Perindopril and nifedipine have similar effects on urinary albumin excretion, both preventing increases in albuminuria in normotensive patients and decreasing albuminuria in hypertensive patients.
OSTEOMYELITIS VARIOLOSA
Authors: W. L. BROWN
Journal: JAMA (1923)

That clinical bone complications during or as a sequel to smallpox is a comparatively rare condition is indicated by a reasonably fair search of the literature, as well as personal inquiries from isolation hospitals. At El Paso, where 390 cases have been treated in the last eight years, there is no history or record of osteomyelitis as a complication or sequel. Councilman<sup>1</sup>states that he has never seen a case of osteomyelitis as a complication of smallpox. Ingelrans and Taconnet,<sup>2</sup>in 500 cases of smallpox, noted osseous lesions consecutive to the infection three times. The evidence seems conclusive that there are two distinct forms of osteomyelitis occurring as complications of smallpox. The ordinary metastatic pyogenic osteomyelitis is the more frequent variety, as indicated by Neve,<sup>3</sup>Bidder,<sup>4</sup>Mauclaire,<sup>5</sup>Paré,<sup>6</sup>Debeyre,<sup>7</sup>Schwenk,<sup>8</sup>Kolaczek<sup>9</sup>and others. That it does not occur more frequently as
Cigaret Smoking Called Hazardous to Health; Discrimination in Medical Societies Opposed
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maternal use of Ginseng and neonatal androgenization
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0211 Studying of the efficiency of the synvisk in osteoparthrosis
Authors: LD Groppa, M Moschneaga
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> At present for improvement of life quality in patients with osteoarthrosis is necessary to solve some problems: precluding of development of degenerative process in cartilage of affected joint, relieving of pain and improving of the function of the joint. <h3>Objectives</h3> <h3>Methods</h3> For these aims we studied the efficiency of the chondroprotective drug Synvisk by Boehringer Ingelheim in 25 patients with arthrosis of the knee in medium age of 61.2 ± 1.7 years, 16 women and 8 men, with duration of the disease 5.8 ± 0.9 years. Conform X-ray data the distribution of the patients by stages of the disease was as follow: I grade ? 20%, II grade ? 64%, and III grade ? 16%. In experimental group the drug was administered intraarticular by blind method in dose of 2.0 ml one time in a week, 3 injections for the course, which were repeated after 6 and 12 months. The control group was matched by gender, duration of disease and X-ray date; in this group was administrated placebo conform same scheme. Evaluation of the effectiveness and tolerability of compared drugs was carried out in evolution of clinical (pain, functional index by Lesquesne, volume of movement on affected joints), X-ray parameters and functional methods (ultrasonography, scintigraphy with Te99m. <h3>Results</h3> In the basic group were mentioned decreasing of the pain intensity and improvement of the joint functions just after single injection in one third of the patients, while in control groups similar cases were absent. After 3 courses of the treatment in the basic group the effects were obtained in 86.7% of the patients, including 33.3% very good effect, in 53.4% moderate effect and only in 13.3% the effects were absent. In control group there were no effects in 80% of the patients, and in 20% of the patients there were mentioned moderate effects; good effects were are not observed. <h3>Conclusion</h3> Thus, presented results suggests that administration of Synvisk lead to significant improvement of the life quality in the patients with arthrosis of the knee.
P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC.
Authors: P. Jänne, H. Yu, N. Shipitofsky, M. Vigliotti, T. Goldberg, J. Li, J. Mcgill, H. Zhang, C. Yu
Journal: Journal of Thoracic Oncology (2018)
Prevalence of non-pneumonic infections with SARS-correlated virus
Authors: Michel Theron
Journal: The Lancet (2004)

Patrick Woo and colleagues1Woo PC Lau SK Tsoi HW et al.Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia.Lancet. 2004; 363: 841-845Summary Full Text Full Text PDF PubMed Scopus (124) Google Scholar use an IgG antibody test combined with western-blot analysis to demonstrate the existence of subclinical or non-pneumonic infections with SARS virus and the prevalence of such cases compared with pneumonic SARS cases. However, the four patients identified as having non-pneumonic SARS were among a group of 33 positive by the authors' ELISA, of whom 26 were also positive by nucleocapsid western blot. Thus, 22 samples turned out to be positive for antibodies against SARS virus nucleocapsid protein, but negative for antibodies against SARS virus spike protein. This high rate of false-positive samples, as the authors qualified them, is difficult to explain because serum samples from patients with OC43 and 229E human coronavirus infections are not cross-reactive with SARS virus.2Ksiazek TG Erdman D Goldsmith CS et al.A novel coronavirus associated with severe acute respiratory syndrome.N Engl J Med. 2003; 348: 1953-1966Crossref PubMed Scopus (3571) Google Scholar Therefore, since SARS-virus structural proteins have shown close sequence identity with those of other viruses, how can the authors be so conclusive with regard to samples that are double-positive by spike and nucleocapsid western blots? Is a second antigen really sufficient to draw such a conclusion, or could it be that spike western blot also led to some false-positive results? The large number of serum samples from non-pneumonic patients that were reactive with SARS virus nucleocapsid protein sheds doubt on the ability of western blotting with SARS virus spike protein to identify truly positive samples, since no clear proof of its specificity over the corresponding blot with nucleocapsid protein has been provided. Prevalence of non-pneumonic infections with SARS-correlated virusAuthors' reply Full-Text PDF